Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) EBT (2020 - 2025)

GeneDx Holdings (WGS) has disclosed EBT for 6 consecutive years, with -$18.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 436.72% to -$18.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$21.1 million, a 59.84% increase, with the full-year FY2025 number at -$21.1 million, up 59.84% from a year prior.
  • EBT was -$18.2 million for Q4 2025 at GeneDx Holdings, down from -$7.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $10.6 million in Q2 2025 to a low of -$308.7 million in Q4 2022.
  • A 5-year average of -$64.3 million and a median of -$41.3 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 280529.9% in 2021, then surged 135.97% in 2025.
  • GeneDx Holdings' EBT stood at -$40.2 million in 2021, then tumbled by 668.12% to -$308.7 million in 2022, then soared by 91.52% to -$26.2 million in 2023, then soared by 120.68% to $5.4 million in 2024, then crashed by 436.72% to -$18.2 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's EBT are -$18.2 million (Q4 2025), -$7.4 million (Q3 2025), and $10.6 million (Q2 2025).